Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Clofarabine in MDS
NCT00299156Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2006
- Primary completion
- Dec 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of clofarabine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission at 24 weeks. Started Mar 2006; status: completed.
02
Drugs
clofarabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00299156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299156.